Australian industry welcomes PBS listing but Pradaxa concerns linger
This article was originally published in Scrip
Australia's health ministry has announced the reimbursement listing of nine drugs under the state-funded Pharmaceutical Benefits Scheme (PBS), including AstraZeneca's platelet anti-aggregant Brilinta (ticagrelor).
You may also be interested in...
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.